Recommendation ID
NG238/3
Question

What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes?

Any explanatory notes
(if applicable)

For a short explanation of why the committee made this recommendation for research, see the rationale section on statins for primary prevention of CVD .

Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects.


Source guidance details

Comes from guidance
Cardiovascular disease: risk assessment and reduction, including lipid modification
Number
NG238
Date issued
December 2023

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 01/01/2024